| Wang, Xiaoshen |
NCT06156891: PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC |
|
|
| Recruiting | 2 | 60 | RoW | Toxicities reduced treatment, Conventional treatment | Fudan University | Oropharyngeal Cancer | 07/25 | 07/25 | | |
NCT06156878: PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy |
|
|
| Recruiting | 2 | 41 | RoW | Anti-EGFR and PD-1 inhibitor arm | Fudan University | Nasopharyngeal Carcinoma | 08/25 | 08/25 | | |
RETICULA-NPC, NCT04921995: Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 40 | RoW | Tislelizumab | Fudan University | Recurrent Nasopharyngeal Carcinoma, Unresectable Nasopharyngeal Carcinoma, Chemotherapy Effect, Immunotherapy, Stereotactic Body Radiation Therapy (SBRT) | 10/22 | 06/24 | | |
NCT04508829: Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy |
|
|
| Recruiting | 2 | 52 | RoW | Anti-EGFR monoclonal antibody | Fudan University | Oropharyngeal Carcinoma | 12/23 | 12/23 | | |
NCT05260671: Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN |
|
|
| Recruiting | 2 | 48 | RoW | Penpulimab combined with cetuximab, AK105+Erbitux | Eye & ENT Hospital of Fudan University | Head and Neck Neoplasms, Recurrent Disease, Metastatic Cancer | 12/24 | 12/26 | | |
NCT05011227: Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 100 | RoW | Camrelizumab, Chemotherapy, endoscopic surgery | Eye & ENT Hospital of Fudan University, Chinese Academy of Medical Sciences | Recurrent Nasopharyngeal Carcinoma | 08/25 | 08/25 | | |
| Recruiting | 2 | 45 | RoW | endoscopic surgery, radiotherapy, chemotherapy, Toripalimab | Eye & ENT Hospital of Fudan University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Malignant Melanoma, Sinonasal Melanoma | 05/26 | 05/26 | | |
NCT05350891: Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC |
|
|
| Recruiting | 2 | 77 | RoW | endoscopic surgery, adjuvant immunotherapy, chemotherapy | Eye & ENT Hospital of Fudan University, Chinese Academy of Medical Sciences | Recurrent Nasopharyngeal Carcinoma | 05/26 | 05/26 | | |
| Recruiting | 1 | 28 | RoW | endoscopic surgery, intensity-modulated radiation therapy or volume of rotating intensity-modulated radiotherapy or Proton or heavy ion radiation therapy, Chemotherapy drug | Eye & ENT Hospital of Fudan University, Chinese Academy of Medical Sciences | Mucosal Melanoma, Sinonasal Melanoma | 08/25 | 08/25 | | |
